| 6 min read
Researchers are moving beyond the male default as evidence reveals how sex influences disease, drug response, and clinical outcomes.
| 4 min read
Two new FDA approvals, a CRISPR program discontinued, discussions of a major merger, and more led the news this week.
| 2 min read
A new alternative approach to antibody-drug conjugates takes advantage of cancer cells’ need for fuel — first by encouraging them to overdose on glucose and then by blocking its backup source of fat.News
| 2 min read
A new study showed environmental bacteria can transfer resistance genes to pathogens inside human lungs that were previously sensitive to antibiotics. The findings could prompt new treatments that block the gene transfer.
| 5 min read
Montara Therapeutics is taking a different approach to CNS drug development by using the blood-brain barrier to restrict drug activity outside the brain and reduce dose-limiting toxicities.
| 3 min read
Analysis of two pivotal Yescarta clinical trials revealed that patients' germline DNA influences both toxicity risk and CAR T expansion, opening new opportunities for smarter cell therapy design.
| 4 min read
Positive results for GLP-1 drugs in alcohol use disorder, a new collaboration to advance in vivo CAR T therapies, Phase 3 readouts in oncology, rare disease, and vitiligo, and more led the news this week.
| 5 min read
Wobble Genomics is using long-read RNA sequencing to reveal the molecular signals that determine whether a cancer treatment will work.
| 4 min read
By tracking how cells respond to hundreds of thousands of compounds, Soley Therapeutics aims to discover medicines for complex diseases where traditional target-based approaches often fall short.
| 3 min read
The science being built right now in discovery labs is what acquirers are already looking for.
| 3 min read
Voyager Therapeutics’ promising toxicology data in non-human primates suggests their proprietary capsid technology could deliver long-lasting results in Alzheimer’s disease.
| 2 min read
The deal brings a first-in-class anti-CD122 antibody with early clinical validation in vitiligo and celiac disease into argenx's pipeline.
